The rapid evolution of treatment strategies for hepatitis C

American Journal of Gastroenterology

Volumn 109, Issue 5, 2014, Pages 628-635

  Muir, Andrew J ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR;

DRUG COST; HEALTH CARE ACCESS; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1 INFECTION; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 2 INFECTION; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 3 INFECTION; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 4 INFECTION; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 5 INFECTION; HEPATITIS C VIRUS GENOTYPE 6; HEPATITIS C VIRUS GENOTYPE 6 INFECTION; HUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TREATMENT DURATION;

ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; INTERFERON-ALPHA; RIBAVIRIN; SULFONAMIDES; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84899970077     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.66     Document Type: Review

References (29)

1. FDA. Soldavi US prescribing information. 2013. http://www.accessdata.fda. gov/drugsatfda-docs/label/2013/204671s000lbl.pdf.
2. Lawitz E, Mangia A, Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
3. FDA. Olysio U.S. prescribing information. 2013. http://www.accessdata. fda. gov/drugsatfda-docs/label/2013/205123s000lbl.pdf.
4. Recommendations for Testing, Managing, and Treating Hepatitis C. 2014 Retrieved from http://hcvguidelines.org/on January 2014.
5. Ghany MG, Strader DB, Thomas DL et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
6. Sulkowski M, Pol S, Mallolas J et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
7. Sulkowski MS, Sherman KE, Dieterich DT et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
8. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-7.
9. Kirk GD, Mehta SH, Astemborski J et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med 2013; 158: 658-66.
10. Ditah I, Ditah F, Devaki P et al. The Changing Epidemiology of Hepatitis C Virus Infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2013; 60: 691-8.
11. Jacobson I, Dore GJ, Foster GR et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-na i ve patients: results from QUEST-1, a phase III trial. J Hepatol 2013; 58 (Suppl 1): S574.
12. Manns MP, Marcellin P, Poordad F et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial. J Hepatol 2013; 58 (Suppl 1): S568.
13. Lawitz E, Forns X, Zeuzem S et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed aft er previous interferon-based therapy: results from PROMISE, a phase III Trial. Gastroenterology 2013; 144 (5 Suppl 1): S151.
14. Zeuzem S, Berg T, Gane E et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014; 146: 430-41.
15. Dieterich DT, Rockstroh J, Orkin C et al. Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype-1 and HIV-1: Primary analysis of the C212 study. 14th European AIDS Conference, October 16-19, 2013, Brussels, Belgium.
16. Osinusi A, Meissner EG, Lee YJ et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310: 804-11.
17. Sulkowski MS, Rodriguez-Torres M, Lalezari JP et al. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Hepatology 2013; 58 (S1): 313A.
18. Jacobson IM, Ghalib R, Rodriguez-Torres M et al. SVR results of a once-daily regimen of simeprevir (SMV, TMC435) plus sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-na i ve and prior null responder patients: The COSMOS study. 2013 The Liver Meeting, Washington, DC. Abstract LB3.
19. Gane EJ, Stedman CA, Hyland RH et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin: the ELECTRON trial. Hepatology 2013; 58 (Suppl 1): 243A.
20. Lawitz E, Poordad F, Hyland RH et al. Once daily sofosbuvir/ledipasvir fixed dose combination with or without ribavirin resulted in. 95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: the LONESTAR trial. Hepatology 2013; 58 (Suppl 1): 315A-6A.
21. Kowdley KV, Lawitz E, Poordad F et al. Safety and efficacy of interferonfree regimens of ABT-450/r, ABT-267, ABT-333 +/ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. J Hepatol 2013; 58 (Suppl 1): S2.
22. Everson GT, Sims KD, Thuluvath PJ et al. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. The 64th Annual Meeting of the American Association for the Study of Liver Diseases, 2013, Washington, DC.
23. Sulkowski MS, Gardiner DF, Rodriguez-Torres M et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
24. Jacobson IM, Gordon SC, Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
25. Zeuzem S, Dusheiko GM, Salupere R et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Hepatology 2013; 58 (Suppl 1): 733A.
26. Lawitz E, Poordad F, Brainard DM et al. Sofosbuvir in combination with pegIFN and ribavirin for 12 weeks provides high SVR rates in HCV-infected genotype 2 or 3 treatment-experienced patients with and without compensated cirrhosis: results from the LONESTAR-2 study. 2013 The Liver Meeting, Washington, DC. Abstract LB4.
27. Ruane PJ, Ain D, Riad J et al. Sofosbuvir plus ribavirin in the treatment of chronic HCV genotype 4 infection in patients of Egyptian Ancestry. Hepatology 2013; 58 (Suppl 1): 736A.
28. Armstrong GL, Wasley A, Simard EP et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-14.
29. Stepanova M, Kanwal F, El-Serag HB et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53: 737-45.